Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
KNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.56 - $28.15
Previous CloseN/A
Volume84.12K
Average Volume (3M)564.09K
Market Cap
$1.41B
Enterprise Value$1.58B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding41,566,826
10 Day Avg. Volume506,467
30 Day Avg. Volume564,086
Standard Deviation0.15
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.71
Price to Cash Flow (P/CF)-159.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.39
Enterprise Value/Ebitda-62.91
Forecast
1Y Price Target
$35.50Price Target Upside80.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Kiniksa Pharmaceuticals News
See All KNSA News
---
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceThe FY25 guide suggests growth isn't slowing, which helps alleviate investor concerns over a slower launch.
Sales GrowthManagement reports significant growth in Arcalyst's US market, driven by all lines of therapy.
Bears Say
Growth ConcernsShares are down, likely driven by fears that Arcalyst growth might be slowing down based on the quarter-on-quarter numbers.
---
Ownership Overview
7.91% Insiders
18.67% Mutual Funds
46.11% Other Institutional Investors
13.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $16.56 and its highest was $28.15 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $1.41B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Oct 29, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.023 by -$0.203.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 41,566,826 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.023. Following the earnings report the stock price went down -15.694%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
---
Kiniksa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (80.29% Upside)
$35.50 (80.29% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 84.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.15%
12-Months-Change
Fundamentals
Return on Equity
-2.08%
Trailing 12-Months
Asset Growth
14.95%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
KNSA Company Deck
---
KNSA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and increased sales guidance, driven by high prescriber satisfaction and effective educational initiatives. However, challenges remain with net losses and patient misdiagnosis rates. Overall, the positive aspects of revenue growth and strategic initiatives outweigh the negatives.Read More>---
KNSA Stock 12 Month Forecast
Average Price Target
$35.50
▲(80.29% Upside)
Technical Analysis
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+24.89%
assigned a buy rating 10 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +24.89% per trade.
---